Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma

Abstract : There is no effective treatment for recurrent glioblastoma (GB) when temozolomide-based radiochemotherapy fails. In theory, intra-arterial (IA) delivery of cytotoxic agents could achieve higher drug concentrations in tumors compared to intravenous injection. Moreover, choosing a highly lipid-soluble drug could make the most of the first-pass effect. Here, we evaluated idarubicin (IDA), a lipophilic anthracycline, in an in vitro assay using four human GB cell lines and compared it with 11 other drugs previously used for the IA treatment of brain tumors. Despite impressive in vitro cytotoxicity, IA IDA did not produce a beneficial effect in 2 patients with recurrent GB. (C) 2016 The Author(s) Published by S. Karger AG, Basel
Type de document :
Article dans une revue
Liste complète des métadonnées
Contributeur : Louise DESSAIVRE Connectez-vous pour contacter le contributeur
Soumis le : samedi 5 mars 2022 - 17:55:07
Dernière modification le : dimanche 4 septembre 2022 - 17:22:28

Lien texte intégral



Mohamad Chehimi, Mathieu Boone, Cyril Chivot, Herve Deramond, Jean-Marc Constans, et al.. Intra-Arterial Delivery of Idarubicin in Two Patients with Glioblastoma. Case Reports in Oncology, Basel : Karger, 2016, 9 (2), pp.499-505. ⟨10.1159/000448654⟩. ⟨hal-03598687⟩



Consultations de la notice